GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.93 USD | -0.56% |
|
-1.75% | -17.38% |
| Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
| Apr. 15 | Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 | MT |
Financials (USD)
| Sales 2024 * | 27.51B | Sales 2025 * | 27.96B | Capitalization | 83.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 6.18B | Net income 2025 * | 6.84B | EV / Sales 2024 * | 3.53 x |
| Net Debt 2024 * | 13.09B | Net Debt 2025 * | 7.12B | EV / Sales 2025 * | 3.26 x |
| P/E ratio 2024 * |
13.9
x | P/E ratio 2025 * |
12.2
x | Employees | 18,000 |
| Yield 2024 * |
4.66% | Yield 2025 * |
4.86% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | -0.56% | ||
| 1 week | -1.75% | ||
| Current month | -8.63% | ||
| 1 month | -8.64% | ||
| 3 months | -22.61% | ||
| 6 months | -16.84% | ||
| Current year | -17.38% |
1 week
66.89
69.03
1 month
66.8974.28
Current year
66.8987.87
1 year
66.8987.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 215 M€ | +12.15% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 66.93 | -0.56% | 5,287,513 |
| 24-04-16 | 67.31 | -0.65% | 4,975,048 |
| 24-04-15 | 67.75 | -0.47% | 7,717,826 |
| 24-04-12 | 68.07 | -0.84% | 5,691,760 |
| 24-04-11 | 68.65 | +0.78% | 6,071,511 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.31
USD
Average target price
86.03
USD
Spread / Average Target
+27.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.38% | 83.93B | |
| +28.79% | 673B | |
| +24.81% | 551B | |
| -7.64% | 348B | |
| +15.00% | 317B | |
| +5.99% | 288B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 195B | |
| -11.71% | 145B |
- Stock Market
- Equities
- GILD Stock
